Trials / Completed
CompletedNCT02016235
Role Of Phosphorus And FGF 23 In Patients With Dent Disease
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Phosphorus Supplement | 250 mg po qid |
| OTHER | Observation | Baseline blood and urine measurements only |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2019-01-01
- Completion
- 2019-01-01
- First posted
- 2013-12-19
- Last updated
- 2020-03-23
- Results posted
- 2020-03-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02016235. Inclusion in this directory is not an endorsement.